# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

> **NCT06707610** · PHASE1 · RECRUITING · sponsor: **Shanghai Allink Biotherapeutics Co., Ltd.** · enrollment: 234 (estimated)

## Conditions studied

- Advanced Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** ALK202

## Key facts

- **NCT ID:** NCT06707610
- **Lead sponsor:** Shanghai Allink Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06707610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06707610, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06707610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*